Myelin oligodendrocyte glycoprotein (MOG) is a minor myelin protein expressed on the surface of oligodendrocytes and on the outermost layer of central nervous system (CNS) myelin sheaths.
It is a type I transmembrane glycoprotein with a single extracellular immunoglobulin-like domain, making it highly accessible to circulating autoantibodies.
The MOG gene lies on chromosome 6p21.3–p22 within the major histocompatibility complex region and is highly conserved across species, suggesting an important structural role in myelin stability.
Physiologically, MOG is thought to contribute to completion and maintenance of compact myelin and to myelin–axon adhesion, rather than primary conduction itself.

🧬 Pathophysiology – Why is MOG Immunologically Important?

Because its Ig-like domain is exposed extracellularly, MOG becomes an easily accessible target for pathogenic IgG autoantibodies.
In MOG antibody-associated disease (MOGAD), these antibodies bind MOG and trigger complement activation, inflammatory cell recruitment, and demyelination within the optic nerves, brain and spinal cord.
The pathology appears more “perivenous and inflammatory” than classic multiple sclerosis (MS), often resembling acute disseminated encephalomyelitis (ADEM) rather than confluent MS plaques on histology.
Unlike AQP4-IgG neuromyelitis optica spectrum disorder (NMOSD), MOGAD is primarily an oligodendrocyte/myelin disorder (rather than astrocytopathy), which helps explain differences in imaging and clinical course.

🧾 Definition – What is MOGAD?

MOG antibody-associated disease (MOGAD) is an inflammatory demyelinating disease of the CNS characterised by:
- a typical acquired demyelinating syndrome (e.g. optic neuritis, myelitis, ADEM, brainstem or cortical encephalitis), and
- serum MOG-IgG positivity detected with a live cell-based assay targeting the extracellular domain of human MOG.
The 2023 International MOGAD Panel criteria emphasise:
- Use of a validated cell-based assay,
- Exclusion of MS and AQP4-IgG NMOSD, and
- Cautious interpretation of low-titre or transient MOG-IgG, especially if the phenotype is atypical.
MOGAD can be monophasic or relapsing, with relapse risk higher in the first few years after onset.

📊 Epidemiology & Clinical Patterns

MOGAD is rare but is now recognised as one of the more common antibody-mediated CNS demyelinating disorders, affecting both children and adults.
In paediatrics it frequently presents with ADEM or multiphasic ADEM; in adults it more often causes optic neuritis (often bilateral) and transverse myelitis.
Common clinical presentations:
- Optic neuritis – visual loss, pain on eye movements; often bilateral and with marked optic disc swelling.
- Transverse myelitis – paraparesis or quadriparesis, sensory level, sphincter disturbance; lesions can be longitudinally extensive but may be shorter than in AQP4-NMOSD.
- ADEM-like presentations – encephalopathy, multifocal deficits, seizures (especially in children).
- Cortical/brainstem encephalitis – focal seizures, cortical deficits, or brainstem sym

The content on this website is provided for educational and informational purposes only to support exam preparation (e.g., MLA, MRCP, USMLE) and learning. This is NOT medical advice, diagnosis, treatment, or professional guidance. It does not replace consultation with a qualified healthcare professional, official guidelines (e.g., NICE, GMC, BNF), or supervised clinical practice. Always verify information with current, authoritative sources. Makindo and its contributors accept no liability for any reliance on this content, including errors, omissions, or any resulting harm, loss, or consequences. By using this site, you agree to these terms.

Myelin Oligodendrocyte Glycoprotein (MOG) &amp; MOG Antibody-Associated Disease (MOGAD)

🔎 About

🧬 Pathophysiology – Why is MOG Immunologically Important?

🧾 Definition – What is MOGAD?

📊 Epidemiology & Clinical Patterns

Categories

Myelin Oligodendrocyte Glycoprotein (MOG) & MOG Antibody-Associated Disease (MOGAD)